Ironwood Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2011. Financial statements are unaudited. The company filed the report on August 12, 2011.
Business context
Ironwood is a development-stage pharmaceutical company with no product sales. Its lead candidate, linaclotide, is being developed for irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC); it is the company’s only candidate with clinical proof of concept. Ironwood reports one operating segment, human therapeutics, and earns revenue principally through collaborations and licensing. Its former biomanufacturing subsidiary, Microbia, was sold in September 2010 and is presented as discontinued operations in prior-period comparisons.
Key financial results
Amounts below are in millions of dollars, except per-share amounts.
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Collaborative arrangements revenue | $11.3 | $9.2 | $21.5 | $18.0 |
| Research and development expense | $19.4 | $19.9 | $39.0 | $37.4 |
| General and administrative expense | $10.8 | $6.6 | $20.0 | $12.4 |
| Total operating expenses | $30.2 | $26.5 | $59.0 | $49.8 |
| Operating loss | $(19.0) | $(17.3) | $(37.5) | $(31.8) |
| Net loss attributable to Ironwood | $(18.8) | $(17.1) | $(37.2) | $(33.1) |
| Net loss per share, basic and diluted | $(0.19) | $(0.18) | $(0.37) | $(0.41) |
Operating expenses exceeded revenue in both periods; the company remained loss-making and reported no product revenue. No conventional product gross margin is presented.
- Cash flow: Six-month operating cash use was $42.1 million, versus $44.5 million in 2010. Investing activities provided $44.0 million, mainly from securities maturities and sales; financing activities provided $1.9 million. Cash and cash equivalents increased $3.9 million to $48.2 million.
- Liquidity: Unrestricted cash, cash equivalents and available-for-sale securities totaled approximately $201.1 million at June 30, 2011. Restricted cash was $7.6 million. Available-for-sale securities were $152.9 million and had contractual maturities of one year or less.
- Balance sheet: Total assets were $249.7 million and stockholders’ equity was $130.1 million. Capital lease obligations totaled approximately $0.8 million. The company reported that long-term debt was repaid in September 2010.
- Other obligations: Minimum linaclotide API and drug-product purchase commitments were approximately $44.8 million through 2017, with the earliest commitments beginning in 2012.
Changes versus prior comparable periods
- Q2 revenue rose 22.6% and first-half revenue rose 19.3%, mainly due to Almirall milestone-related revenue, a revised estimate of the Almirall development period, and increased clinical-material shipments. Forest collaboration revenue was approximately unchanged.
- Q2 R&D expense declined 2.5%, primarily as linaclotide trial and manufacturing costs fell after the IBS-C and CC trials were completed in 2010. For the first half, R&D expense increased 4.1%, as lower linaclotide costs were more than offset by increased staffing, Protagonist-related costs, facilities and consulting.
- G&A expense increased 63.7% in Q2 and 61.7% for the first half, reflecting increased headcount, share-based compensation, expanded facilities and preparation for potential commercialization.
- Net loss attributable to Ironwood increased by $1.7 million in Q2 and $4.2 million for the first half. First-half 2010 included discontinued-operation losses from Microbia; Microbia was sold in September 2010.
Outlook, management commentary and notable items
- On August 9, 2011, Ironwood and Forest announced submission of a U.S. NDA for linaclotide for IBS-C and CC. The filing said Ironwood expected an increase in collaboration revenue in the second half of 2011 if FDA acceptance of the NDA triggered Forest milestone payments of up to $20 million. Payment is contingent, not assured.
- Almirall anticipated submitting a European marketing application for linaclotide for IBS-C in the second half of 2011.
- Management expects substantial losses to continue for the foreseeable future and stated that available resources, together with potential collaborator milestone payments, were expected to support operations through at least 2014. This forecast is subject to risks and could prove inaccurate.
- Ironwood revised its estimated Almirall development period from 50 to 41 months in June 2011, increasing recognized revenue by approximately $0.5 million in both Q2 and the first half. The company adopted new multiple-deliverable and milestone revenue guidance prospectively; adoption had no material reported impact.
- In January 2011, Ironwood entered a Protagonist discovery collaboration and expensed an approximately $2.8 million upfront payment. In July 2011, after quarter-end, it licensed Depomed’s Acuform drug-delivery technology and said it would make an upfront payment; the filing does not provide a clear value for that payment.
- Linaclotide development and commercialization depend on regulatory approval, collaborators and third-party manufacturers. The filing identifies diarrhea as the most common adverse event in Phase 3 trials: 14%–20% of treated patients experienced it, and it led to study discontinuation in 3%–6%.
- Other key risks include clinical or regulatory delays or rejection, manufacturing and supply interruptions, partner performance, uncertain market adoption and reimbursement, competition, intellectual-property disputes, and the need for additional capital. Revenue is concentrated among Forest, Almirall and Astellas; together they represented all continuing-operations revenue in the reported periods.
Important facts for investors to verify
- FDA review milestones, possible NDA acceptance, approval timing and any requested labeling or post-approval requirements for linaclotide.
- Whether the anticipated Forest milestone is achieved and paid, and the timing and amount of any other collaboration milestones.
- Almirall’s European filing progress and the status of regulatory development in Astellas territories.
- Manufacturing readiness, supply capacity and the $44.8 million minimum purchase commitments, including associated cash requirements.
- Cash burn, spending on commercialization and pipeline programs, and whether the company’s qualified runway estimate through at least 2014 remains supportable.
- Linaclotide’s safety profile, commercial uptake, pricing and reimbursement, and the company’s dependence on collaboration partners and concentrated revenue sources.